|Day Low/High||6.10 / 6.68|
|52 Wk Low/High||3.60 / 12.60|
H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.
Conference Call Scheduled August 10, 2016 at 4:30 p.m. EDT
Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations
Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT
Preclinical Data Presented at the AACR 2016 Meeting
-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --
Levi & Korsinsky announces it has commenced an investigation of Cyclacel Pharmaceuticals, Inc.
Company to Present at the Biotech Showcase(TM) 2016 Conference
In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting
Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST
CYC065 Predicted to be Effective in Leukemia and Triple Negative Breast Cancer
Mechanistic Rationale of CYC065 in Targeted Solid Tumors and Hematology
Conference Call Scheduled August 11, 2015 at 4:30 p.m. EDT